From "HA dermal filler" to "collagen dermal filler" and then to "ECM injection," the generational shift in medical aesthetics injectables is essentially a migration of value proposition: consumers are no longer satisfied with the cycle of "fill it in, let it metabolize, fill it again," but instead expect materials to induce their own tissue to complete structural repair. Understanding this migration is key to reading the medical aesthetics industry over the next five years.
It is worth noting that HA remains the largest single product category to date—data from reportsanddata shows that the global HA market was approximately $12.85 billion in 2025, projected to reach $31.75 billion by 2035, with a CAGR of 9.4%, of which skin filling and injectable aesthetics applications account for 42.6%. But the market structure is changing: growth in traditional HA fillers is slowing, while "HA + regeneration" combination protocols (immediate HA support + long-term regeneration via collagen stimulators) are becoming the mainstream clinical approach. This shows that filling and regeneration are not a substitute relationship, but a combination relationship—the rise of ECM-based materials does not overturn fillers, but upgrades filling from a "one-time delivery" to a "structural investment."
I. The Evolution Path of Medical Aesthetics Materials: Why Move from "Filling" to "Regeneration"
Hyaluronic acid (HA) fillers became the global gold standard for soft tissue filling around 2003. Their essence is "physical occupation + water absorption": cross-linked HA takes effect immediately after injection, but as hyaluronidase degrades it and it is metabolized in the body, the effect returns to zero after 6–18 months, requiring repeated injections. Collagen injectables appeared earlier, but were constrained by animal-derived allergy rates and sourcing issues until recombinant humanized collagen technology matured and brought them back to the stage. The third generation is "regenerative materials"—from PLLA (poly-L-lactic acid stimulating autologous collagen encapsulation) to dECM (decellularized ECM) materials, the logic has changed from "I fill it for you" to "I induce you to grow it yourself." There are three drivers toward regeneration: first, the effect of fillers is "borrowed," returning to zero upon metabolism, leading to repeated-consumption fatigue; second, consumer demand for "naturalness, durability, and structural improvement" continues to rise; third, clinical evidence and regulatory frameworks are beginning to recognize the real value of regenerative materials in tissue repair, which is precisely why "regenerative aesthetic medicine" has become a high-frequency industry term.
II. Clinical Application Layers
1. Injectable filling (HA/collagen). HA fillers use cross-linking degree and elastic modulus (G') to determine support strength and duration, and are used for nasolabial folds, apple cheeks, chin, and other areas from the mid-dermis to deep dermis; collagen injectables are more suitable for fine lines, tear troughs, and other delicate areas, combining immediate filling with subsequent stimulation of autologous collagen deposition.
2. Collagen stimulators (PLLA-type). PLLA takes effect gradually 1–3 months after injection, with autologous collagen encapsulating microspheres to form "collagen hyperplasia," and the effect can last 18–24 months; PCL microspheres + CMC gel (youthful injection type) combines immediate filling with long-acting stimulation and takes effect faster.
3. dECM microparticles/gel. After micronization, decellularized ECM has injectable conditions and is used for soft tissue repair and depression filling. Its core value is inducing host cell ingrowth and promoting autologous ECM deposition. Allogeneic ECM products have been approved in China, but indications are strictly limited (see the regulatory section for details). "Injectable-grade ECM" is in the clinical translation window for Class III device registration.
4. ECM patches. Used in wound healing and postoperative repair scenarios, providing a moist healing environment and growth signals. This is an extended category for post-medical-aesthetics recovery management, and also the lowest-threshold, fastest-to-commercialize form of ECM technology.
III. Mechanism Comparison: Physical Filling vs Endogenous Regeneration
Physical filling (HA, immediate-type collagen) is "result-oriented": occupation + water absorption + immediately visible, with predictable effects, but it fades as the material degrades. Safety hinges on cross-linkers and injection layer. Endogenous regeneration (dECM, PLLA) is "process-oriented": ECM provides a "natural microenvironment"—a three-dimensional scaffold structure, cell adhesion sequences such as RGD, and growth factor-binding sites—recruiting macrophages toward a reparative phenotype (M2), activating fibroblasts to synthesize autologous collagen and GAG, and achieving gradual, structural tissue improvement. In one sentence: filling gives an "effect," while regeneration gives a "process." The peak effect of regenerative materials appears months later and is closer to physiological repair. This is also the underlying logic for why injectable-grade recombinant collagen ("recombinant collagen injection") is regarded as the next-generation mainstream material—the signals it leaves during degradation are exactly the language most familiar to host tissue.
At the mechanistic level, consider another set of key differences: the effect of physical filling depends on the "material itself," and once the material is exhausted, the effect returns to zero; the effect of regenerative materials depends on the "host response," and the material is only a scaffold and signal carrier. The quality of the host response depends on four things: the immunogenicity of the material (whether decellularization is thorough and whether the recombinant sequence is humanized), the match between degradation rate and new tissue deposition rate, whether the injection layer is in a well-vascularized area rich in fibroblasts, and the patient's own repair capacity. Therefore, the "slow onset" of regenerative materials is not a defect, but an inevitable result of being synchronized with physiological repair—this also requires doctors to retrain their injection philosophy: filling is "instant delivery," regeneration is "project management."
IV. Market Data: The Regeneration Track Is Scaling Up
| Market | 2025 | Forecast | Growth Rate | Source |
|---|---|---|---|---|
| Global ECM market | $2.15 billion | $3.81 billion by 2032 | CAGR 8.5% | pmarketresearch |
| Global recombinant collagen market | $4.12 billion | $23.84 billion by 2032 | CAGR 28.5% (medical aesthetics applications account for 45%) | pmarketresearch |
| Global recombinant humanized collagen market | $2.15 billion | $9.42 billion by 2032 | CAGR 23.5% (cosmetics and skincare account for 65%) | pmarketresearch |
| Global collagen market | $5.85 billion | $11.8 billion by 2035 | CAGR 7.3% | reportsanddata |
| HA dermal filler market | $5.44 billion | $11 billion by 2034 | CAGR 8.14% | marketdataforecast |
| China ECM product market | Approximately RMB 10.7 billion (2025) | — | — | Cross-validation from multiple industry sources |
Two comparisons are telling: HA dermal fillers have a large base but steady growth (about 8%), and the "filling" track has entered stock-market competition; while recombinant collagen leads with a 28.5% CAGR, and medical aesthetics applications account for 45% of its share—injectable-grade recombinant collagen and ECM regenerative materials are dual hotspots for capital and clinical practice.
Current status of Class III device registration in China and industry developments (36Kr 2026-09 industry observation): ECM has evolved from membrane sheets to micronized forms with injectable conditions; regulators limit the indications of some allogeneic ECM products to "excluding facial wrinkle removal," leaving differentiated space for segmented indications; Bloomage Biotech's humanized biomimetic ECM Class III device has entered pilot testing; Aimeike invested in Huaxia Biology to obtain exclusive ECM distribution rights; Huadong Medicine reached an exclusive cooperation with Meibai Biology for the ECM collagen product MB007—upstream raw materials and channel players are rapidly binding, and the registration window countdown has begun.
V. Regulation and Safety: Hard Constraints of Class III Regulation
Injectable-grade ECM and recombinant collagen products are managed as Class III medical devices and require registration testing, animal experiments, multicenter controlled clinical trials, and system audits, with registration cycles measured in years. Indication boundaries must be watched: approved indications are usually precise to anatomical site and clinical use, and some ECM products are explicitly limited to "excluding facial wrinkle removal." Off-label use is the main gray risk in the real world. Real-world risks also include: nodules and granulomas (especially with collagen stimulators), vascular embolism (wrong injection layer can cause skin necrosis or even blindness), and immune reactions (immunogenicity control of allogeneic ECM, virus and pathogen inactivation validation). For institutions, choosing compliant products with complete Class III registration certificates and standardized injection training is the bottom line for medical safety and the starting point for brand differentiation.
VI. Industry Landscape: Upstream Scarcity, Midstream Positioning
Upstream raw material suppliers are currently the scarcest link. The recombinant collagen track has already produced multiple listed companies, while what is truly scarce on the dECM raw material side is decellularization technology, quality control systems, and scalable production capacity—Weitai Group's velubio is precisely a supplier of collagen/ECM biological raw materials for this industry segment. Midstream brands and institutions have three opportunities: first, differentiated indication positioning (avoiding the red ocean of "facial wrinkle removal" and focusing on depression repair, periorbital area, postoperative repair, etc.); second, "regenerative combination therapy" protocols (full-cycle management of ECM injection + photoelectric + postoperative ECM patches, which is also a segment where zhenmeifu Class II device dressing OEM can collaborate); third, exporting doctor education and real-world evidence downstream to build academic barriers.
VII. One Outlook Sentence
The speed at which "filling" is replaced by "regeneration" depends on the purity, stability, and scalability of upstream raw materials—the next explosive point in ECM medical aesthetics will most likely emerge at the intersection of the raw material end and the indication innovation end.
Further Reading: To learn more about one-stop cosmetics and medical aesthetics OEM services, please visit Zhenmeifu; for collagen and ECM raw material supply, please visit Velubio.